in Taiwan
May 4, 2021 – release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has launched VYZULTA
® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan. Regulatory approval in Taiwan was obtained in March 2020. VYZULTA has also recently received approval in Qatar.
In addition to Taiwan, VYZULTA is commercialized in the United States (since 2017), Canada (2019), Argentina (2020), Mexico (2020) and Hong Kong (2020), and is now approved in 5 other territories (Brazil, Colombia, Qatar, South Korea, and Ukraine). VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication. Bausch + Lomb will continue seeking approvals in t
Operator
Ladies and gentlemen, thank you for standing by. Good morning and welcome to Alimera Sciences First Quarter Fiscal Year 2021 Financial Results and Corporate Update Conference Call. [Operator Instructions] After today s presentation, there will be an opportunity to ask questions. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded by a playback-purposes. A webcast replay of the call will be available approximately one hour after the end of the call through May 13, 2021.
I would now like to turn the call over to Mr. Scott Gordon of CORE IR, the company s Investor Relations firm.Please go ahead, sir.
and
for future
value as we continue the development of our clinical assets NCX 470 in glaucoma and NCX 4251 in blepharitis.”
Latanoprostene bunod, the pharmaceutical active ingredient in VYZULTA, was invented and patented by Nicox, and is the first product from the company’s proprietary nitric oxide-donating research platform to be approved for commercialization. Under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (also known as the “Hatch-Waxman Act”) certain patents for pharmaceutical products in the U.S. may be extended by up to 5 years once product approval from the FDA has been obtained.
Allogene Therapeutics (ALLO)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Allogene Therapeutics, with a price target of $43.00. The company’s shares closed last Wednesday at $35.12.
According to TipRanks.com, Burns is a 4-star analyst with an average return of 15.5% and a 44.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Allogene Therapeutics with a $46.50 average price target, implying a 42.8% upside from current levels. In a report issued on April 12, Oppenheimer also assigned a Buy rating to the stock with a $52.00 price target.